ArticleScientific reports2026
Therapeutic Potential of GYY4137 in Reducing Oxidative Stress and Mortality in Experimental Decompression Sickness.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiology of decompression sickness (DCS) is not fully understood. Apart from bubble formation, endothelial dysfunction and reactive oxygen species (ROS) production, participate in DCS. We aimed to evaluate the redox profile (redox potential, adenosine deaminase activity (ADA), and xanthine oxidase activity (XO) and the effects of GYY4137, an H2S donor with antiradical properties, on the mortality of mice exposed to experimental DCS. Sixty Mice were injected intraperitoneally with either GYY4137 or saline, then subjected to high pressure in a hyperbaric chamber, followed by a quick decompression. GYY4137 increased survival with a median lethal dose (LD50) of 120 m compared with those injected with saline (< 100 m; p = 0.038) but did not affect significantly ADA or XO activities. The redox potential (RP: mV) was lower in the GYY4137 group (median-range, 116[78–189]) than that in the saline group: 150[88–226], p = 0.04. Experimental DCS itself was associated with an increase in RP. We concluded that GYY4137 protects mice while reducing RP and ROS production. Our results seem to indicate that the reduction of the redox potential induced by the administration of H2S donor could reduce mortality during DCS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.